Amyloid PET scans will be interpreted by physicians board-certified in radiology or nuclear medicine and who have completed the vendor-provided, tracer-specific training program provided for each radiopharmaceutical that they will use. The physician must also consent to participate in the study and to adhere to protocol procedures.
Participating facilities and interpreting physicians will be reimbursed for global or technical and professional services, respectively, provided to the Medicare beneficiary patient, under CMS Coverage with Evidence Development, which requires research study participation as a condition of Medicare payment.
The PET images will be collected for this study via TRIAD, proprietary software which de-identifies images at a site and enables online transmission.
The New IDEAS study is currently reaching out to dementia specialists in areas identified by our community engagement and recruitment team. Those practices are asked to identify which imaging facility they would plan on referring their patients to. The study team will reach out to the imaging facilities that are identified. If you have not been contacted by the study and would like to be considered as a participating facility, please send an email to newideas@acr.org.
Participation in New IDEAS requires the submission of a site feasibility questionnaire and subsequent approval by the study. Information about the New IDEAS study will also be disseminated via professional organizations dedicated to neurology, psychiatry, geriatrics, nuclear medicine and radiology.
Access the feasibility questionnaire for imaging facilities.
The New IDEAS study will include the three amyloid PET imaging radiopharmaceuticals that have been approved by the U.S. Food and Drug Administration (FDA) for clinical use:
Amyloid PET tracers that have not been approved by the FDA for clinical use will not be included in the New IDEAS study.